Table 1 Clinical characteristics of screened patients
From: Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality
Characteristic* | Overall Group (n = 53)* | Non-Metformin User (n = 26) | Metformin User (n = 27) | P-value‡ |
|---|---|---|---|---|
|  |  | No. (%) or Mean ± SD |  | |
Age – yrs | 76.5 ± 8.6 | 78.2 ± 8.5 | 74.9 ± 8.7 | 0.17 |
Sex – male | 30 (57) | 16 (62) | 14 (52) | 0.48 |
Weight (kg) | 82 ± 25 | 80 ± 22 | 84 ± 28 | 0.74 |
Serum Creatinine (μmol/L) | 135 ± 64 | 147 ± 75 | 123 ± 49 | 0.17 |
Creatinine Clearance (ml/min) | 49 ± 23 | 45 ± 18 | 53 ± 26 | 0.19 |
A1c (%)†| 7.3 ± 0.02 | 6.8 ± 1.2 | 7.7 ± 2.6 | 0.22 |
Heart Failure Medications | Â | Â | Â | Â |
   Beta-Blockers | 38 (72) | 18 (69) | 20 (74) | 0.70 |
   ACE Inhibitors or ARBs | 51 (96) | 26 (100) | 25 (93) | 0.49 |
   Calcium Channel Blockers | 18 (34) | 8 (31) | 10 (37) | 0.63 |
   Antiplatelet Agents | 44 (83) | 21 (81) | 23 (85) | 0.73 |
   Digoxin | 9 (17) | 4 (15) | 5 (19) | 1.0 |
   Spironolactone | 12 (23) | 5 (19) | 7 (26) | 0.56 |
   Lipid Therapy | 41 (77) | 19 (73) | 22 (82) | 0.47 |
   Nitrates | 10 (19) | 4 (15) | 6 (22) | 0.73 |
Diabetes Medications | Â | Â | Â | Â |
   Insulin | 23 (43) | 15 (58) | 8 (30) | 0.039 |
   Sulfonylureas | 8 (15) | 3 (12) | 5 (19) | 0.70 |
   Thiazolidinediones | 4 (8) | 1 (4) | 3 (11) | 0.61 |
   Meglitinides | 2 (4) | 1 (4) | 1 (4) | 1.00 |